Forging Ahead In Vitiligo: Incyte’s Ruxolitinib Cream Scores Phase II Win
Executive Summary
The topical version of Jakafi will move into Phase III later this year for the autoimmune disease after a strong Phase II showing.
Topics
- Subjects
- Clinical Trials
- Research & Development
- Therapy Areas
- Immune Disorders
- Dermatology
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC125403
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC125403
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.